Achieve Life Sciences, Inc. (ACHV)
NASDAQ: ACHV · Real-Time Price · USD
4.620
-0.160 (-3.35%)
At close: Dec 5, 2025, 4:00 PM EST
4.630
+0.010 (0.21%)
After-hours: Dec 5, 2025, 7:57 PM EST
Company Description
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Achieve Life Sciences, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Richard A. Stewart |
Contact Details
Address: 22722 29th Dr. SE, Suite 100 Bothell, Washington 98021 United States | |
| Phone | 604 210 2217 |
| Website | achievelifesciences.com |
Stock Details
| Ticker Symbol | ACHV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000949858 |
| CUSIP Number | 004468203 |
| ISIN Number | US0044685008 |
| Employer ID | 95-4343413 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Richard A. B. Stewart | Chief Executive Officer and Executive Director |
| Mark K. Oki CPA | Chief Financial Officer |
| Craig Donnelly | Chief Operations Officer |
| Jerry Wan | Vice President of Finance and Principal Accounting Officer |
| Erik Atkisson | Chief Legal Officer |
| Jaime Xinos | Chief Commercial Officer |
| Dr. Mark L. Rubinstein | Interim Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 6, 2025 | 10-Q | Quarterly Report |
| Nov 6, 2025 | 8-K | Current Report |
| Oct 7, 2025 | 8-K | Current Report |
| Sep 11, 2025 | 8-K | Current Report |
| Aug 14, 2025 | SCHEDULE 13G | Filing |
| Aug 7, 2025 | 10-Q | Quarterly Report |
| Aug 7, 2025 | 8-K | Current Report |
| Aug 5, 2025 | SCHEDULE 13G/A | Filing |